Corvus Pharmaceuticals Stock Today
| CRVS Stock | USD 4.31 0.10 2.38% |
PerformanceVery Weak
| Odds Of DistressBelow Average
|
Corvus Pharmaceuticals is selling for under 4.31 as of the 23rd of March 2025; that is 2.38 percent increase since the beginning of the trading day. The stock's lowest day price was 4.0. Corvus Pharmaceuticals has about a 42 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 23rd of December 2024 and ending today, the 23rd of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 23rd of March 2016 | Category Healthcare | Classification Health Care |
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. The company was incorporated in 2014 and is based in Burlingame, California. Corvus Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 64.26 M outstanding shares of which 5.73 M shares are currently shorted by private and institutional investors with about 10.26 trading days to cover. More on Corvus Pharmaceuticals
Moving together with Corvus Stock
Moving against Corvus Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Corvus Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President | William Jones | |||||||||||||||||||||||||||||||||||
| Thematic Idea | Cancer Fighters (View all Themes) | |||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||
Debt LevelsCorvus Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Corvus Pharmaceuticals' financial leverage. It provides some insight into what part of Corvus Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||
Corvus Pharmaceuticals (CRVS) is traded on NASDAQ Exchange in USA. It is located in 863 Mitten Road, Burlingame, CA, United States, 94010 and employs 28 people. Corvus Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 276.95 M. Corvus Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 64.26 M outstanding shares of which 5.73 M shares are currently shorted by private and institutional investors with about 10.26 trading days to cover.
Corvus Pharmaceuticals currently holds about 56.72 M in cash with (23.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.22.
Check Corvus Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationCorvus Pharmaceuticals holds a total of 64.26 Million outstanding shares. Over half of Corvus Pharmaceuticals' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Corvus Ownership Details
Corvus Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Goldman Sachs Group Inc | 2024-12-31 | 584.5 K | |
| Geode Capital Management, Llc | 2024-12-31 | 566.9 K | |
| Sphera Funds Management Ltd. | 2024-12-31 | 500.5 K | |
| Ghost Tree Capital, Llc | 2024-09-30 | 500 K | |
| Qube Research & Technologies | 2024-12-31 | 450.1 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 397.4 K | |
| Renaissance Technologies Corp | 2024-12-31 | 390.7 K | |
| State Street Corp | 2024-12-31 | 205.5 K | |
| Millennium Management Llc | 2024-12-31 | 154.9 K | |
| Orbimed Advisors, Llc | 2024-12-31 | 6.9 M | |
| Samlyn Capital, Llc | 2024-12-31 | 6.7 M |
Corvus Pharmaceuticals Historical Income Statement
Corvus Stock Against Markets
Corvus Pharmaceuticals Corporate Management
| Leiv Lea | Chief Officer | Profile | |
| James MD | Senior Research | Profile | |
| Alan Esq | Sec | Profile | |
| MD FACP | CoFounder Director | Profile | |
| Jeffrey Arcara | Chief Officer | Profile |
Additional Tools for Corvus Stock Analysis
When running Corvus Pharmaceuticals' price analysis, check to measure Corvus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corvus Pharmaceuticals is operating at the current time. Most of Corvus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corvus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corvus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corvus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.